EGP-1214

EGP-1214 is a sublingual/intraoral compressed tablet formulation of human recombinant insulin developed by EastGate Pharmaceuticals (EastGate Biotech Corp.) for the treatment of Type 2 diabetes and pre-diabetes. Utilizing proprietary nanotechnology, the drug is designed for transmucosal delivery under the tongue, providing a non-invasive alternative to traditional subcutaneous insulin injections. By bypassing the digestive system and delivering insulin directly into the bloodstream through the oral mucosa, EGP-1214 aims to improve blood glucose management and patient compliance. The company is pursuing the 505(b)(2) regulatory pathway for approval in various international markets, including Canada, Mexico, and Malaysia.

Other names

sublingual insulin tabletintraoral insulin tablet